
Hofseth Biocare ASA
OSE:HBC

Intrinsic Value
The intrinsic value of one
HBC
stock under the Base Case scenario is
4.07
NOK.
Compared to the current market price of 2.06 NOK,
Hofseth Biocare ASA
is
Undervalued by 49%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Hofseth Biocare ASA
Fundamental Analysis


Revenue & Expenses Breakdown
Hofseth Biocare ASA
Balance Sheet Decomposition
Hofseth Biocare ASA
Current Assets | 112.1m |
Cash & Short-Term Investments | 25.6m |
Receivables | 18.9m |
Other Current Assets | 67.6m |
Non-Current Assets | 229.3m |
Long-Term Investments | 48.9m |
PP&E | 138m |
Intangibles | 42.4m |
Other Non-Current Assets | 1k |
Free Cash Flow Analysis
Hofseth Biocare ASA
NOK | |
Free Cash Flow | NOK |
Earnings Waterfall
Hofseth Biocare ASA
Revenue
|
257.4m
NOK
|
Cost of Revenue
|
-169.6m
NOK
|
Gross Profit
|
87.9m
NOK
|
Operating Expenses
|
-201.1m
NOK
|
Operating Income
|
-113.2m
NOK
|
Other Expenses
|
-10.2m
NOK
|
Net Income
|
-123.4m
NOK
|
HBC Profitability Score
Profitability Due Diligence
Hofseth Biocare ASA's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Score
Hofseth Biocare ASA's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
HBC Solvency Score
Solvency Due Diligence
Hofseth Biocare ASA's solvency score is 25/100. The higher the solvency score, the more solvent the company is.

Score
Hofseth Biocare ASA's solvency score is 25/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HBC Price Targets Summary
Hofseth Biocare ASA
Dividends
Current shareholder yield for HBC is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
HBC
stock under the Base Case scenario is
4.07
NOK.
Compared to the current market price of 2.06 NOK,
Hofseth Biocare ASA
is
Undervalued by 49%.